Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study

Documenti analoghi

• Effective Management of PASS Syndrome With Intravenous Immunoglobulin and Anti‐Interleukin‐1 Therapy: An Insightful Case Study
  di: Ji‐Won Kim, et al.
  Pubblicazione: (2025)
• Letter: Risk Prediction Model for HCC in Subjects Without Apparent Chronic Liver Disease: A Dilemma in Asia. Author's Reply
  di: Byeong Geun Song, et al.
  Pubblicazione: (2025)
• Pharmacological characteristics of once‐weekly insulin icodec in Japanese individuals with type 1 diabetes
  di: Takashi Eto, et al.
  Pubblicazione: (2024)
• Superconducting Diode Effect in Double Quantum Dot Device
  di: Takeuchi, Go, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetic and Pharmacodynamic Modeling of Romiplostim Biosimilar GP40141 and Reference Product in Healthy Volunteers to Evaluate Biosimilarity
  di: Igor Makarenko, et al.
  Pubblicazione: (2024)